Chile Eliminates Leprosy: A WHO Milestone & Disease Overview

In a landmark achievement for global public health, Chile has been officially verified by the World Health Organization (WHO) as having eliminated leprosy, also known as Hansen’s disease. This makes Chile the first country in the Americas – and only the second globally – to reach this milestone, signaling a significant step forward in the fight against this ancient, chronic infectious disease. The announcement, made on March 4, 2026, underscores the power of sustained public health initiatives and commitment to accessible healthcare.

Understanding Leprosy: A Disease Rooted in History

Leprosy is caused by the bacterium Mycobacterium leprae, which primarily affects the skin, peripheral nerves, and upper respiratory tract. Left untreated, it can lead to progressive and permanent damage, resulting in disabilities. However, it’s crucial to understand that leprosy is not highly infectious and is transmitted through droplets from the nose and mouth during close, frequent contact with untreated individuals. The disease has a remarkably long incubation period, averaging five years, but symptoms can take up to two decades to manifest. Early symptoms often include pale or reddish skin patches with a loss of sensation, painless ulcers, and muscle weakness.

Historically, leprosy carried a heavy social stigma, leading to isolation and the creation of leper colonies. Today, modern public health approaches prioritize stigma-free, integrated care, recognizing that early diagnosis and treatment are key to preventing disabilities. The disease itself has a long history, with evidence of its existence found in ancient civilizations across China, Egypt, and India. In Chile, leprosy was first recorded at the end of the 19th century, initially concentrated on Rapa Nui (Easter Island), where it was managed through isolation and treatment measures until the late 1990s.

Chile’s Path to Elimination: A Three-Decade Vigil

While historically present on Easter Island, leprosy remained limited on mainland Chile. Since 1993, Chile has not reported any locally acquired cases of leprosy. However, the country maintained a vigilant approach, keeping leprosy a notifiable condition and integrating surveillance into its healthcare system. This continuous monitoring, combined with long-term political commitment, proved essential in achieving elimination status. The WHO verification recognizes over thirty years of sustained public health action, robust surveillance systems, and a health system prepared to respond even in the absence of local transmission.

The success in Chile is built on the foundation of Multi-Drug Therapy (MDT), a combination of rifampicin, dapsone, and clofazimine, which the WHO has provided globally for free since the 1980s. MDT offers a 100% cure rate for leprosy, and early treatment is vital in preventing the debilitating effects of the disease. As Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, stated, Chile’s achievement demonstrates that eliminating leprosy is achievable with sustained commitment, inclusive health services, and universal access to care.

Beyond Chile: The Global Leprosy Landscape

Chile’s accomplishment serves as a powerful example for other nations striving to eliminate leprosy. While Chile is the first in the Americas, it is the second country globally to achieve this status. The WHO continues to work with countries around the world to strengthen surveillance, improve access to MDT, and combat the stigma associated with the disease. According to PAHO Director Dr. Jarbas Barbosa, Chile’s success demonstrates the importance of building strong health systems capable of detecting, responding to, and providing comprehensive care for those affected by leprosy, including those living with chronic disabilities.

What Does Elimination Mean? And What Remains?

It’s important to clarify what “elimination” signifies in this context. It does not mean the complete absence of leprosy globally. Rather, it indicates that a country has interrupted indigenous transmission of the disease. Chile will continue to monitor for imported cases and maintain its surveillance systems to prevent re-establishment of local transmission. The WHO emphasizes that ongoing vigilance is crucial, even after verification, to ensure sustained progress.

Looking Ahead: Sustaining Progress and Global Efforts

The WHO and PAHO are committed to supporting other countries in the Americas and beyond in their efforts to eliminate leprosy. This includes strengthening surveillance systems, improving access to early diagnosis and treatment, and addressing the social stigma that often prevents people from seeking care. Future efforts will also focus on identifying and treating individuals with disabilities resulting from past leprosy infections, providing them with rehabilitation services and ensuring their full inclusion in society. The success in Chile provides a roadmap for other nations, demonstrating that with sustained commitment and strategic investment, the goal of a leprosy-free world is within reach.

The ongoing process involves continuous review of surveillance data, adaptation of public health strategies based on emerging evidence, and collaboration between national governments, international organizations, and local communities. Individuals concerned about potential exposure or experiencing symptoms consistent with leprosy should consult with a qualified healthcare professional for accurate diagnosis and appropriate treatment.